The novel observation that PARP inhibition or knockdown activates the PI3K/mTOR pathway in SCLC (Fig 1) is consistent with our previously published report that this pathway is the strongest marker of baseline resistance to PARP inhibition [5]. This evidence concerns the gene PARP1 and small cell lung carcinoma.